vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and FREQUENCY ELECTRONICS INC (FEIM). Click either name above to swap in a different company.
CytomX Therapeutics, Inc. is the larger business by last-quarter revenue ($18.7M vs $17.1M, roughly 1.1× FREQUENCY ELECTRONICS INC). FREQUENCY ELECTRONICS INC runs the higher net margin — 10.5% vs -0.8%, a 11.3% gap on every dollar of revenue. On growth, FREQUENCY ELECTRONICS INC posted the faster year-over-year revenue change (8.3% vs -25.7%). FREQUENCY ELECTRONICS INC produced more free cash flow last quarter ($-1.1M vs $-15.8M). Over the past eight quarters, FREQUENCY ELECTRONICS INC's revenue compounded faster (11.8% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
Ultra Electronics Holdings is a British defence and security company. It was listed on the London Stock Exchange and was a constituent of the FTSE 250 Index until it was acquired by Cobham, which is itself owned by Advent International.
CTMX vs FEIM — Head-to-Head
Income Statement — Q2 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $17.1M |
| Net Profit | $-154.0K | $1.8M |
| Gross Margin | — | 38.2% |
| Operating Margin | -6.9% | 10.0% |
| Net Margin | -0.8% | 10.5% |
| Revenue YoY | -25.7% | 8.3% |
| Net Profit YoY | 97.6% | -32.1% |
| EPS (diluted) | — | $0.18 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $17.1M | ||
| Q3 25 | — | $13.8M | ||
| Q2 25 | $18.7M | $20.0M | ||
| Q1 25 | $50.9M | $18.9M | ||
| Q4 24 | $38.1M | $15.8M | ||
| Q3 24 | $33.4M | $15.1M | ||
| Q2 24 | $25.1M | $15.6M | ||
| Q1 24 | $41.5M | $13.7M |
| Q4 25 | — | $1.8M | ||
| Q3 25 | — | $634.0K | ||
| Q2 25 | $-154.0K | $3.2M | ||
| Q1 25 | $23.5M | $15.4M | ||
| Q4 24 | $18.9M | $2.7M | ||
| Q3 24 | $5.7M | $2.4M | ||
| Q2 24 | $-6.5M | $2.6M | ||
| Q1 24 | $13.8M | $130.0K |
| Q4 25 | — | 38.2% | ||
| Q3 25 | — | 36.8% | ||
| Q2 25 | — | 37.5% | ||
| Q1 25 | — | 43.8% | ||
| Q4 24 | — | 48.2% | ||
| Q3 24 | — | 44.4% | ||
| Q2 24 | — | 40.3% | ||
| Q1 24 | — | 22.6% |
| Q4 25 | — | 10.0% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | -6.9% | 16.4% | ||
| Q1 25 | 44.4% | 18.3% | ||
| Q4 24 | 46.4% | 16.5% | ||
| Q3 24 | 12.3% | 15.7% | ||
| Q2 24 | -33.7% | 16.0% | ||
| Q1 24 | 28.1% | -3.4% |
| Q4 25 | — | 10.5% | ||
| Q3 25 | — | 4.6% | ||
| Q2 25 | -0.8% | 16.0% | ||
| Q1 25 | 46.2% | 81.4% | ||
| Q4 24 | 49.6% | 16.8% | ||
| Q3 24 | 17.2% | 16.1% | ||
| Q2 24 | -26.0% | 16.9% | ||
| Q1 24 | 33.3% | 0.9% |
| Q4 25 | — | $0.18 | ||
| Q3 25 | — | $0.07 | ||
| Q2 25 | — | $0.33 | ||
| Q1 25 | — | $1.60 | ||
| Q4 24 | — | $0.28 | ||
| Q3 24 | — | $0.25 | ||
| Q2 24 | — | $0.28 | ||
| Q1 24 | — | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $3.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $119.9M | $58.5M |
| Total Assets | $175.1M | $92.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $3.0M | ||
| Q3 25 | — | $4.5M | ||
| Q2 25 | $49.0M | $4.7M | ||
| Q1 25 | $47.6M | $5.5M | ||
| Q4 24 | $38.1M | $9.7M | ||
| Q3 24 | $40.6M | $16.2M | ||
| Q2 24 | $43.2M | $18.3M | ||
| Q1 24 | $36.2M | $11.7M |
| Q4 25 | — | $58.5M | ||
| Q3 25 | — | $56.3M | ||
| Q2 25 | $119.9M | $55.6M | ||
| Q1 25 | $25.0M | $51.8M | ||
| Q4 24 | $-456.0K | $36.2M | ||
| Q3 24 | $-23.5M | $33.2M | ||
| Q2 24 | $-31.2M | $39.8M | ||
| Q1 24 | $-31.7M | $36.7M |
| Q4 25 | — | $92.3M | ||
| Q3 25 | — | $93.2M | ||
| Q2 25 | $175.1M | $93.7M | ||
| Q1 25 | $98.5M | $86.4M | ||
| Q4 24 | $120.5M | $77.8M | ||
| Q3 24 | $139.0M | $84.3M | ||
| Q2 24 | $159.2M | $83.3M | ||
| Q1 24 | $184.7M | $77.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $-523.0K |
| Free Cash FlowOCF − Capex | $-15.8M | $-1.1M |
| FCF MarginFCF / Revenue | -84.6% | -6.6% |
| Capex IntensityCapex / Revenue | 0.1% | 3.6% |
| Cash ConversionOCF / Net Profit | — | -0.29× |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | $-5.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-523.0K | ||
| Q3 25 | — | $1.2M | ||
| Q2 25 | $-15.8M | $-155.0K | ||
| Q1 25 | $-21.0M | $-3.6M | ||
| Q4 24 | $-19.9M | $3.8M | ||
| Q3 24 | $-20.7M | $-1.5M | ||
| Q2 24 | $-19.5M | $7.5M | ||
| Q1 24 | $-26.0M | $4.2M |
| Q4 25 | — | $-1.1M | ||
| Q3 25 | — | $385.0K | ||
| Q2 25 | $-15.8M | $-786.0K | ||
| Q1 25 | $-21.2M | $-4.0M | ||
| Q4 24 | $-20.0M | $3.3M | ||
| Q3 24 | $-20.7M | $-1.8M | ||
| Q2 24 | $-19.6M | $6.7M | ||
| Q1 24 | $-26.2M | $3.9M |
| Q4 25 | — | -6.6% | ||
| Q3 25 | — | 2.8% | ||
| Q2 25 | -84.6% | -3.9% | ||
| Q1 25 | -41.6% | -20.9% | ||
| Q4 24 | -52.5% | 20.8% | ||
| Q3 24 | -62.1% | -11.8% | ||
| Q2 24 | -78.2% | 42.8% | ||
| Q1 24 | -63.1% | 28.4% |
| Q4 25 | — | 3.6% | ||
| Q3 25 | — | 5.6% | ||
| Q2 25 | 0.1% | 3.2% | ||
| Q1 25 | 0.2% | 1.7% | ||
| Q4 24 | 0.2% | 3.3% | ||
| Q3 24 | 0.1% | 2.2% | ||
| Q2 24 | 0.4% | 5.3% | ||
| Q1 24 | 0.3% | 2.3% |
| Q4 25 | — | -0.29× | ||
| Q3 25 | — | 1.83× | ||
| Q2 25 | — | -0.05× | ||
| Q1 25 | -0.89× | -0.24× | ||
| Q4 24 | -1.05× | 1.44× | ||
| Q3 24 | -3.61× | -0.60× | ||
| Q2 24 | — | 2.85× | ||
| Q1 24 | -1.89× | 32.36× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
FEIM
| POC Revenue | $14.8M | 86% |
| POT Revenue | $2.3M | 13% |
